Market Place
Sourcing Support
GT Bio Reports Q3 2025 Financials & Corporate Update
14 Nov 2025 //
GLOBENEWSWIRE
GT Bio Updates Enrollment In GTB-3650 Phase 1 Trial For R/R CD33
23 Oct 2025 //
GLOBENEWSWIRE
Next-Gen Targeted Therapies Transform Oncology Precision Care
15 Oct 2025 //
PR NEWSWIRE BIO
GT Biopharma Updates Enrollment in Ph 1 GTB-3650 r/r CD33 Trial
08 Oct 2025 //
GLOBENEWSWIRE
Novel Cancer Platforms Unite As Data Redefines Treatment Paths
07 Oct 2025 //
PR NEWSWIRE
GT Bio To Participate Centurion One Capital Annual Summit
06 Oct 2025 //
GLOBENEWSWIRE
Gt Biopharma to Join H.C. Wainwright Global Investment Confernece
04 Sep 2025 //
GLOBENEWSWIRE
GT Biopharma Reports Second Quarter 2025 Financial Results
14 Aug 2025 //
GLOBENEWSWIRE
GT Biopharma Advances GTB-3650 Ph 1 Trial to Cohort 3
11 Aug 2025 //
GLOBENEWSWIRE
GT Biopharma Appoints New Member to its Board of Directors
13 Jun 2025 //
GLOBENEWSWIRE
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2
19 May 2025 //
GLOBENEWSWIRE
GT Biopharma Appoints New Member to its Board of Directors
15 May 2025 //
GLOBENEWSWIRE
GT Biopharma Appoints New Member to its Board of Directors
14 May 2025 //
GLOBENEWSWIRE
GT Biopharma To Join 10th Innate Killer Summit Anniversary
04 Mar 2025 //
GLOBENEWSWIRE
GT Biopharma Announces Exercise of Warrants
25 Feb 2025 //
GLOBENEWSWIRE
GT Biopharma Doses First Patient In Phase 1 GTB-3650 Trial
27 Jan 2025 //
GLOBENEWSWIRE
GT Biopharma Reports Third Quarter 2024 Financial Results
14 Nov 2024 //
GLOBENEWSWIRE
GT Biopharma To Participate In ROTH Healthcare Conference
26 Sep 2024 //
GLOBENEWSWIRE
GT Biopharma to Host Virtual Event on NK Cell Engager Oct 10
24 Sep 2024 //
GLOBENEWSWIRE
GT Biopharma Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
GT Announces FDA Clearance of Investigational IND Application for GTB-3650
27 Jun 2024 //
GLOBENEWSWIRE
GT Biopharma Announces $3.2M Registered Direct Offering
21 May 2024 //
GLOBENEWSWIRE
GT Biopharma Reports Q1 2024 Financial Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
01 Feb 2024 //
GLOBENEWSWIRE
GT Biopharma Stockholders Vote FOR All Proposed Items at Special Meeting
06 Dec 2023 //
GLOBENEWSWIRE
GT Bio Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
04 Dec 2023 //
GLOBENEWSWIRE
GT Biopharma Presented Positive Preclinical Data for GTB-5550
06 Nov 2023 //
GLOBENEWSWIRE
GT Biopharma Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
GT Biopharma Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
GT Biopharma to Participate in H.C. Wainwright Immune Cell Engager Conference
03 Aug 2023 //
GLOBENEWSWIRE
GT Biopharma Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
GT Biopharma Names Charles J. Casamento to the Board of Directors
04 May 2023 //
GLOBENEWSWIRE
GT Biopharma Reports 4Q and Reports 2022 FYR and Provides Corporate Update
30 Mar 2023 //
GLOBENEWSWIRE
GT Biopharma to Participate in Wainwright Cell Therapy Virtual Conference
24 Feb 2023 //
GLOBENEWSWIRE
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
02 Feb 2023 //
GLOBENEWSWIRE
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering
30 Dec 2022 //
GLOBENEWSWIRE
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
14 Dec 2022 //
GLOBENEWSWIRE
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting
12 Dec 2022 //
GLOBENEWSWIRE
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach
03 Nov 2022 //
GLOBENEWSWIRE
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results
31 Oct 2022 //
GLOBENEWSWIRE
GT Biopharma Announces Two Poster Presentations at the (SITC) 37th Meeting
06 Oct 2022 //
GLOBENEWSWIRE
GT Biopharma Announces Adjournment of Special Shareholders Meeting
04 Oct 2022 //
GLOBENEWSWIRE
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022
12 Sep 2022 //
GLOBENEWSWIRE
GT Biopharma to Participate in the H.C. Wainwright 24th Annual GHC in September
08 Sep 2022 //
GLOBENEWSWIRE
Cytovance Signs Service Agreement with GT Biopharma
02 Sep 2022 //
CONTRACTPHARMA
Cytovance Signs Service Agreement with GT Biopharma
02 Sep 2022 //
CONTRACT PHARMA
GT Biopharma Affirms Manufacturing Timeline For Lead Asset GTB-3650
30 Aug 2022 //
GLOBENEWSWIRE
GT Biopharma Reports Second Quarter Fiscal 2022 FY Results & Business Update
11 Aug 2022 //
GLOBENEWSWIRE
GT Biopharma Presents PC Data on Second-Gen CD19 Targeting TriKE
10 Jun 2022 //
GLOBENEWSWIRE
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
GT Biopharma to Participate at H.C. Wainwright Hybrid Conference
12 May 2022 //
GLOBENEWSWIRE
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+GTB-5550 at AACR
11 Apr 2022 //
GLOBENEWSWIRE
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results
28 Mar 2022 //
PRNEWSWIRE
GT Biopharma Presents GTB-5550 Preclinical MM Proof-of-Concept Data
21 Mar 2022 //
PRNEWSWIRE
GT Bio Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE
09 Mar 2022 //
PRNEWSWIRE
GT Biopharma Appoints Manu Ohri as Chief Financial Officer
18 Feb 2022 //
PRNEWSWIRE
GT BioPharma Reports Q3 2021 Financial Results and Provides Corporate Update
10 Nov 2021 //
PRNEWSWIRE
GT Biopharma Advances GTB-3650 Into IND-Enabling Studies
13 Sep 2021 //
BIOSPACE
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform
09 Sep 2021 //
BIOSPACE
